Hydroxychloroquine induces oxidative DNA damage and mutation in mammalian cells

Hu, 2020, Characteristics of SARS-CoV-2 and COVID-19, Nat. Rev. Microbiol., 1 V’Kovski, 2020, Coronavirus biology and replication: implications for SARS-CoV-2, Nat. Rev. Microbiol., 1 Sanders, 2020, Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review, Jama, 323, 1824 Dehelean, 2020, SARS-CoV-2: repurposed drugs and novel therapeutic approaches-insights into chemical structure-biological activity and toxicological screening, J. Clin. Med., 9, 2084, 10.3390/jcm9072084 McKee, 2020, Candidate drugs against SARS-CoV-2 and COVID-19, Pharmacol. Res., 157, 10.1016/j.phrs.2020.104859 Sahoo, 2021, Drug repurposing strategy (DRS): emerging approach to identify potential therapeutics for treatment of novel coronavirus infection, Front. Mol. Biosci., 8, 10.3389/fmolb.2021.628144 Saag, 2020, Misguided use of Hydroxychloroquine for COVID-19: the infusion of politics into science, Jama, 324, 2161, 10.1001/jama.2020.22389 Wang, 2020, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res., 30, 269, 10.1038/s41422-020-0282-0 Yao, 2020, In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Clin. Infect. Dis., 71, 732, 10.1093/cid/ciaa237 Liu, 2020, Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Discov., 6, 16, 10.1038/s41421-020-0156-0 Castelli, 2020, Cytokine storm in COVID-19: “When You Come Out of the Storm, You Won’t Be the Same Person Who Walked in”, Front. Immunol., 11, 2132, 10.3389/fimmu.2020.02132 Mehta, 2020, COVID-19: consider cytokine storm syndromes and immunosuppression, Lancet, 395, 1033, 10.1016/S0140-6736(20)30628-0 Food and Drug Administration (FDA), 2020 Food and Drug Administration (FDA), 2020 Abella, 2021, Efficacy and safety of Hydroxychloroquine vs placebo for pre-exposure SARS-CoV-2 prophylaxis among health care workers: a randomized clinical trial, JAMA Intern. Med., 181, 195, 10.1001/jamainternmed.2020.6319 Boulware, 2020, A randomized trial of Hydroxychloroquine as postexposure prophylaxis for Covid-19, N. Engl. J. Med., 383, 517, 10.1056/NEJMoa2016638 Cavalcanti, 2020, Hydroxychloroquine with or without Azithromycin in mild-to-Moderate Covid-19, N. Engl. J. Med., 383, 2041, 10.1056/NEJMoa2019014 Horby, 2020, Effect of Hydroxychloroquine in hospitalized patients with Covid-19, N. Engl. J. Med., 383, 2030, 10.1056/NEJMoa2022926 Schrezenmeier, 2020, Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology, Nat. Rev. Rheumatol., 16, 155, 10.1038/s41584-020-0372-x Ferreira, 2021, Chloroquine and hydroxychloroquine in antitumor therapies based on autophagy-related mechanisms, Pharmacol. Res., 168, 10.1016/j.phrs.2021.105582 Devarajan, 2021, Hydroxychloroquine can potentially interfere with immune function in COVID-19 patients: mechanisms and insights, Redox Biol., 38, 10.1016/j.redox.2020.101810 Tett, 1993, Insights from pharmacokinetic and pharmacodynamic studies of hydroxychloroquine, Agents Actions Suppl., 44, 145 Ballabio, 2020, Lysosomes as dynamic regulators of cell and organismal homeostasis, Nat. Rev. Mol. Cell Biol., 21, 101, 10.1038/s41580-019-0185-4 Vitte, 2020, Immune modulation as a therapeutic option during the SARS-CoV-2 outbreak: the case for antimalarial aminoquinolines, Front. Immunol., 11, 2159, 10.3389/fimmu.2020.02159 Collins, 2018, Hydroxychloroquine: a physiologically-based pharmacokinetic model in the context of cancer-related autophagy modulation, J. Pharmacol. Exp. Ther., 365, 447, 10.1124/jpet.117.245639 Marinković, 2018, Autophagy modulation in cancer: current knowledge on action and therapy, Oxid. Med. Cell. Longev., 2018, 10.1155/2018/8023821 Amaravadi, 2019, Targeting autophagy in Cancer: recent advances and future directions, Cancer Discov., 9, 1167, 10.1158/2159-8290.CD-19-0292 White, 2015, The role for autophagy in cancer, J. Clin. Invest., 125, 42, 10.1172/JCI73941 Levy, 2017, Targeting autophagy in cancer, Nat. Rev. Cancer, 17, 528, 10.1038/nrc.2017.53 Giri, 2020, Mutagenic, Genotoxic and Immunomodulatory effects of Hydroxychloroquine and Chloroquine: a review to evaluate its potential to use as a prophylactic drug against COVID-19, Genes Environ., 42, 25, 10.1186/s41021-020-00164-0 Uzar, 2012, Hydroxycloroquine-induced oxidative stress on sciatic nerve and muscle tissue of rats: a stereological and biochemical study, Hum. Exp. Toxicol., 31, 1066, 10.1177/0960327111433183 Piao, 2017, ALDH1A1 and HLTF modulate the activity of lysosomal autophagy inhibitors in cancer cells, Autophagy, 13, 2056, 10.1080/15548627.2017.1377377 Klouda, 2020, Oxidative stress, proton fluxes, and chloroquine/hydroxychloroquine treatment for COVID-19, Antioxidants Basel (Basel), 9, 894, 10.3390/antiox9090894 Gregório, 2021, Chloroquine may induce endothelial injury through lysosomal dysfunction and oxidative stress, Toxicol. Appl. Pharmacol., 414, 10.1016/j.taap.2021.115412 Richard, 2020, Elucidating the pivotal immunomodulatory and anti-inflammatory potentials of chloroquine and hydroxychloroquine, J. Immunol. Res., 2020, 10.1155/2020/4582612 Caliri, 2021, Relationships among smoking, oxidative stress, inflammation, macromolecular damage, and cancer, Mutat. Res., 787, 10.1016/j.mrrev.2021.108365 Caliri, 2020, Spontaneous and photosensitization-induced mutations in primary mouse cells transitioning through senescence and immortalization, J. Biol. Chem., 295, 9974, 10.1074/jbc.RA120.014465 David, 2007, Base-excision repair of oxidative DNA damage, Nature, 447, 941, 10.1038/nature05978 Cadet, 2017, Formation and repair of oxidatively generated damage in cellular DNA, Free Radic. Biol. Med., 107, 13, 10.1016/j.freeradbiomed.2016.12.049 Besaratinia, 2018, The lambda select cII mutation detection system, J. Vis. Exp., 57510 Besaratinia, 2005, DNA lesions induced by UV A1 and B radiation in human cells: comparative analyses in the overall genome and in the p53 tumor suppressor gene, Proc. Natl. Acad. Sci. U.S.A., 102, 10058, 10.1073/pnas.0502311102 Besaratinia, 2018, Mutation analysis in cultured cells of transgenic rodents, Int. J. Mol. Sci., 19, E262, 10.3390/ijms19010262 White, 2019, In vitro mammalian cell mutation assays based on transgenic reporters: a report of the International Workshop on Genotoxicity Testing (IWGT), Mutat. Res., 847 Lotteau, 1990, Intracellular transport of class II MHC molecules directed by invariant chain, Nature, 348, 600, 10.1038/348600a0 Münz, 2016, Autophagy beyond intracellular MHC class II antigen presentation, Trends Immunol., 37, 755, 10.1016/j.it.2016.08.017 Ghislat, 2018, Autophagy in dendritic cells, Cell. Mol. Immunol., 15, 944, 10.1038/cmi.2018.2 Henderson, 2003, The hydantoin lesions formed from oxidation of 7,8-dihydro-8-oxoguanine are potent sources of replication errors in vivo, Biochemistry, 42, 9257, 10.1021/bi0347252 Neeley, 2006, Mechanisms of formation, genotoxicity, and mutation of guanine oxidation products, Chem. Res. Toxicol., 19, 491, 10.1021/tx0600043 Besaratinia, 2009, In vitro recapitulating of TP53 mutagenesis in hepatocellular carcinoma associated with dietary aflatoxin B1 exposure, Gastroenterology, 137, 1127, 10.1053/j.gastro.2009.06.002 Besaratinia, 2002, Mutational signature of the proximate bladder carcinogen N-hydroxy-4-acetylaminobiphenyl: inconsistency with the p53 mutational spectrum in bladder cancer, Cancer Res., 62, 4331 Besaratinia, 2007, Riboflavin activated by ultraviolet A1 irradiation induces oxidative DNA damage-mediated mutations inhibited by vitamin C, Proc. Natl. Acad. Sci. U.S.A., 104, 5953, 10.1073/pnas.0610534104 Besaratinia, 2005, Investigating DNA adduct-targeted mutagenicity of tamoxifen: preferential formation of tamoxifen-DNA adducts in the human p53 gene in SV40 immortalized hepatocytes but not endometrial carcinoma cells, Biochemistry, 44, 8418, 10.1021/bi0503753 Besaratinia, 2008, Rapid repair of UVA-induced oxidized purines and persistence of UVB-induced dipyrimidine lesions determine the mutagenicity of sunlight in mouse cells, FASEB J., 22, 2379, 10.1096/fj.07-105437 Kim, 2007, Lack of mutagenicity of acrolein-induced DNA adducts in mouse and human cells, Cancer Res., 67, 11640, 10.1158/0008-5472.CAN-07-2528 Besaratinia, 2003, Weak yet distinct mutagenicity of acrylamide in mammalian cells, J. Natl. Cancer Inst., 95, 889, 10.1093/jnci/95.12.889 Besaratinia, 2012, A high-throughput next-generation sequencing-based method for detecting the mutational fingerprint of carcinogens, Nucleic Acids Res., 40, e116, 10.1093/nar/gks610 Munster, 2002, Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis, Arthritis Rheum., 46, 1460, 10.1002/art.10307 Karasic, 2019, Effect of Gemcitabine and nab-paclitaxel with or without hydroxychloroquine on patients with advanced pancreatic Cancer: a phase 2 randomized clinical trial, JAMA Oncol., 5, 993, 10.1001/jamaoncol.2019.0684 Costedoat-Chalumeau, 2006, Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus, Arthritis Rheum., 54, 3284, 10.1002/art.22156 Lyngbakken, 2020, A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine on coronavirus disease 2019 viral kinetics, Nat. Commun., 11, 5284, 10.1038/s41467-020-19056-6 Self, 2020, Effect of hydroxychloroquine on clinical status at 14 days in hospitalized patients with COVID-19: a randomized clinical trial, Jama, 324, 2165, 10.1001/jama.2020.22240 Cui, 2021, Effects of chloroquine or hydroxychloroquine treatment on non-SARS-CoV2 viral infections: a systematic review of clinical studies, Rev. Med. Virol. Abdelrahman, 2021, Evaluation of the current therapeutic approaches for COVID-19: a systematic review and a meta-analysis, Front. Pharmacol., 12, 10.3389/fphar.2021.607408 Gatti, 2021, Drug repurposing in the COVID-19 era: insights from case studies showing pharmaceutical peculiarities, Pharmaceutics, 13, 302, 10.3390/pharmaceutics13030302 Joshi, 2021, Exploring insights of hydroxychloroquine, a controversial drug in Covid-19: an update, Food Chem. Toxicol., 151, 10.1016/j.fct.2021.112106 Cutler, 1988, Pharmacokinetics and cellular uptake of 4-aminoquinoline antimalarials, Agents Actions Suppl., 24, 142 Tett, 1993, Concentration-effect relationship of hydroxychloroquine in rheumatoid arthritis--a cross sectional study, J. Rheumatol., 20, 1874 Rainsford, 2015, Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases, Inflammopharmacology, 23, 231, 10.1007/s10787-015-0239-y Jorge, 2018, Hydroxychloroquine retinopathy - implications of research advances for rheumatology care, Nat. Rev. Rheumatol., 14, 693, 10.1038/s41584-018-0111-8 In’ t Veld, 2021, Hydroxychloroquine effects on TLR signalling: underexposed but Unneglectable in COVID-19, J. Immunol. Res., 2021 Srinivasa, 2017, Increased incidence of gastrointestinal side effects in patients taking hydroxychloroquine: a brand-related issue?, J. Rheumatol., 44, 398, 10.3899/jrheum.161063 Juurlink, 2020, Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection, Cmaj, 192, E450, 10.1503/cmaj.200528 Gisondi, 2021, The safety profile of hydroxychloroquine: major cutaneous and extracutaneous adverse events, Clin. Exp. Rheumatol. Doyno, 2021, Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose, Clin Toxicol (Phila), 59, 12, 10.1080/15563650.2020.1817479